VicPlas International Ltd. (SG:569)
SGX:569
Top Page
VicPlas International Ltd.
(SGX:569)
Select Model
Select Model
Rating:42Neutral
Price Target:
S$0.08
▼(-6.67% Downside)
Action:ReiteratedDate:03/24/26
The score is primarily held back by weaker financial performance—recent losses, deteriorating cash generation, and rising leverage—while technicals are mildly negative with the stock below key moving averages. Valuation is also pressured due to a negative P/E and no stated dividend yield.
Positive Factors
Diversified revenue streams
VicPlas’s dual-segment model (piping systems and medical devices) provides durable revenue diversification across construction and healthcare end markets. Structural demand in both sectors reduces single-market dependence and supports resilience if one end market weakens over the next several months.
Negative Factors
Rising leverage
A rising debt-to-equity ratio signals increased reliance on external financing and higher fixed obligations. Over the medium term this constrains financial flexibility, raises interest burden risk, and reduces capacity for strategic investment if cash generation does not improve.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified revenue streams
VicPlas’s dual-segment model (piping systems and medical devices) provides durable revenue diversification across construction and healthcare end markets. Structural demand in both sectors reduces single-market dependence and supports resilience if one end market weakens over the next several months.
Read all positive factors
VicPlas International Ltd. (569) vs. iShares MSCI Singapore ETF (EWS)
Market Cap
S$44.46M
Dividend YieldN/A
Average Volume (3M)97.25K
Price to Earnings (P/E)―
Beta (1Y)0.56
Revenue Growth13.07%
EPS Growth-70.37%
CountrySG
Employees1,000
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding511,537,700
10 Day Avg. Volume66,350
30 Day Avg. Volume97,253
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)0.65
Price to Sales (P/S)0.39
P/FCF Ratio-7.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
VicPlas International Ltd. Business Overview & Revenue Model
Company Description
Vicplas International Ltd, an investment holding company, engages in the medical devices, and pipes and pipe fittings businesses in Singapore, Malaysia, the People's Republic of China, and the United Kingdom. The company manufactures, trades, and ...
VicPlas International Ltd. Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
55
Neutral
Cash Flow
34
Negative
| Breakdown | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 | Jul 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 120.81M | 102.39M | 129.22M | 130.81M | 113.94M |
| Gross Profit | 66.57M | 52.42M | 66.19M | 68.06M | 60.84M |
| EBITDA | 7.01M | 6.93M | 13.18M | 17.93M | 19.03M |
| Net Income | -2.36M | -1.36M | 4.24M | 8.84M | 10.40M |
Balance Sheet | |||||
| Total Assets | 137.71M | 131.49M | 119.02M | 130.34M | 111.66M |
| Cash, Cash Equivalents and Short-Term Investments | 4.71M | 4.97M | 8.57M | 8.89M | 9.87M |
| Total Debt | 41.11M | 32.47M | 17.55M | 28.01M | 19.57M |
| Total Liabilities | 66.32M | 56.93M | 40.46M | 52.03M | 40.01M |
| Stockholders Equity | 71.39M | 74.57M | 78.56M | 78.31M | 71.64M |
Cash Flow | |||||
| Free Cash Flow | -5.99M | -7.82M | 12.53M | -2.61M | 3.83M |
| Operating Cash Flow | 388.00K | 6.72M | 17.88M | 10.25M | 9.01M |
| Investing Cash Flow | -6.36M | -14.53M | -5.10M | -12.79M | -5.16M |
| Financing Cash Flow | 5.75M | 4.24M | -12.76M | 1.63M | 1.86M |
VicPlas International Ltd. Technical Analysis
Negative
0.09
Price Trends
0.09
Negative
0.09
Negative
0.09
Negative
Market Momentum
>-0.01
Negative
47.69
Neutral
54.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:569, the sentiment is Negative. The current price of 0.09 is above the 20-day moving average (MA) of 0.09, below the 50-day MA of 0.09, and below the 200-day MA of 0.09, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 47.69 is Neutral, neither overbought nor oversold. The STOCH value of 54.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:569.
VicPlas International Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
SG:569
VicPlas International Ltd.
0.09
<0.01
4.82%
SG:1B1
HC Surgical Specialists Ltd
0.37
0.11
40.68%
SG:546
Medtecs International Corporation Ltd.
0.11
-0.02
-11.72%
SG:8YY
Biolidics Ltd.
0.05
0.03
117.39%
SG:FRQ
Singapore Paincare Holdings Limited
0.09
-0.02
-17.92%
SG:MIJ
Alliance Healthcare Group Ltd.
0.16
0.06
55.45%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.